The MPN Hub was pleased to speak to Aaron Gerds, Cleveland Clinic Taussig Cancer Institute, Cleveland, US. Gerds discussed treating anemia in patients with myelofibrosis (MF).

Gerds highlights the impact of anemia on survival outcomes in patients with MF, and reviews key data from the phase II ACE-536-MF-001 trial (NCT03194542) evaluating the safety and efficacy of luspatercept in patients with MF and anemia, including patients with and without transfusion dependence and concurrent Janus kinase (JAK) inhibition. He then highlights the ongoing randomized, phase III INDEPENDENCE trial (NCT04717414) assessing the safety and efficacy of luspatercept in combination with ruxolitinib in transfusion-dependent patients with MF. Finally, Gerds discusses potential future combinations of luspatercept with ACVR1 inhibitors. 

This educational resource is independently supported by Bristol Myers Squibb. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.

Hosted on Acast. See acast.com/privacy for more information.